Literature DB >> 3229014

The use and abuse of 0.05 per cent clobetasol propionate in dermatology.

D W Harris1, J A Hunter.   

Abstract

In conclusion, there can be no doubt that CP is a remarkable local steroid with potency greater than anything previously available to the dermatologist. It may be useful for short-term (less than 2 weeks) and intermittent treatment of widespread inflammatory dermatoses. It is excellent for treating some stubborn localized inflammatory dermatoses before moving on to more dilute preparations. When prescribing CP, it is important to warn the patient of common side effects, such as atrophy and striae, and to instruct the patient carefully in its use, mentioning body areas that should be spared its application. CP should not be applied to flexural, scrotal, or, with a few exceptions such as discoid lupus erythematosus and actinic reticuloid, facial skin. Its use is contraindicated in infants, toddlers, and children under 12 years of age. In addition, adult patients must be told never to use more than 50 gm per week (the manufacturer's recommendation). The prescribing physician must monitor and regularly review the amount used per unit time. Treatment with CP beyond 2 weeks is not recommended in the product information on CP listed in the Physicians' Desk Reference (1988). Those few patients taking CP for a long period should be managed as though they are on systemic steroids. Episodes of acute stress, such as surgery and intercurrent infection, should be managed with supplemental, if necessary parenteral, glucocorticoid administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3229014

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  3 in total

Review 1.  Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.

Authors:  Therdpong Tempark; Voraluk Phatarakijnirund; Susheera Chatproedprai; Suttipong Watcharasindhu; Vichit Supornsilchai; Siriwan Wananukul
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

2.  Topical steroid abuse: its use as a depigmenting agent.

Authors:  Edith Nnoruka; Obiefuna Okoye
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

3.  In Vivo Assessment of Clobetasol Propionate-Loaded Lecithin-Chitosan Nanoparticles for Skin Delivery.

Authors:  Taner Şenyiğit; Fabio Sonvico; Alessandra Rossi; Işıl Tekmen; Patrizia Santi; Paolo Colombo; Sara Nicoli; Özgen Özer
Journal:  Int J Mol Sci       Date:  2016-12-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.